Pancreatic and nephrotoxicity of immunomodulator compounds
- 1 December 1995
- journal article
- review article
- Published by Elsevier in Toxicology Letters
- Vol. 82-83, 99-105
- https://doi.org/10.1016/0378-4274(95)03471-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A Risk-Benefit Assessment of Tacrolimus in TransplantationDrug Safety, 1995
- Mechanism of FK506-induced glucose intolerance in rats.The Journal of Toxicological Sciences, 1994
- SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1993
- Renal actions of endothelin peptidesCurrent Opinion in Nephrology and Hypertension, 1993
- FK506-INDUCED KIDNEY TUBULAR CELL INJURYTransplantation, 1992
- Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicityKidney International, 1992
- FK506 AS AN AGONIST TO INDUCE INHIBITION OF INTERLEUKIN 2 PRODUCTIONTransplantation, 1992
- MORPHOLOGICAL AND FUNCTIONAL CHANGES OF ISLETS OF LANGERHANS IN FK506-TREATED RATSTransplantation, 1992
- Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexesCell, 1991
- Role of endothelin in cyclosporine-induced glomerular dysfunctionKidney International, 1990